Ecaprinil-D

Quick links to important sections

Ecaprinil-D

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ecaprinil-D

Property Description
Active ingredient Enalapril Maleate and Hydrochlorothiazide (HCTZ)
Form Tablet (Oral)
Pharmacological class Antihypertensive Agent
Common use High blood pressure (Essential Hypertension)
Origin Synthetic

Ecaprinil-D: Identity and Pharmacological Class

Ecaprinil-D is a prescription-only medication classified as a dual-mechanism Antihypertensive Agent, provided as a synthetic oral tablet. This product is defined as a fixed-dose combination (FDC) because it unites two distinct active substances, Enalapril Maleate and Hydrochlorothiazide (HCTZ), within a single formulation. The FDC structure is clinically recognized for enhancing patient adherence by simplifying the daily regimen for individuals managing essential hypertension.


Composition and Pharmacological Classes

The core of Ecaprinil-D’s composition involves the combination of an ACE Inhibitor and a Thiazide Diuretic. Enalapril Maleate belongs to the Angiotensin-Converting Enzyme Inhibitor class, which is established for its critical role in affecting the hormonal control of blood pressure. The second component, Hydrochlorothiazide, is a diuretic specifically categorized as a Thiazide Diuretic, which modifies the body's fluid and electrolyte balance. The integration of these two powerful pharmacological classes ensures comprehensive action against elevated blood pressure.


General Purpose of This Combination Therapy

The overall purpose of this combination therapy is the effective and sustained reduction of high blood pressure through complementary mechanisms of effect. The ACE Inhibitor component helps to relax and widen the blood vessels, while the Thiazide Diuretic component aids the body in removing excess salt and water. This dual approach maximizes antihypertensive activity by simultaneously decreasing peripheral resistance and reducing circulating fluid volume, which in turn lessens the overall strain on the cardiovascular system.

Regulatory References

  1. Enalapril: MedlinePlus Drug Information

What side effects are possible with Ecaprinil-D?

Possible Side Effects and Safety Information

The safety profile of Ecaprinil-D, a fixed-dose combination of Enalapril Maleate and Hydrochlorothiazide, is based on adverse reactions documented and classified by government regulatory authorities.

Frequency and System Classification

Adverse reactions are grouped by the likelihood of occurrence and the affected physiological system. Side effects officially classified as common (ge 1/100 to < 1/10) include headache, cough, dizziness, and fatigue. These effects primarily involve the Nervous System and the Respiratory System, consistent with the pharmacological class of the medication.

Adverse reactions that are classified as uncommon include symptomatic hypotension and syncope. Rare effects (ge 1/10,000 to < 1/1,000) may affect the Skin and Subcutaneous Tissue (e.g., Angioedema) or the Hepatobiliary System (e.g., hepatic failure).

Serious Adverse Reactions and Key Constraints

The most clinically significant adverse reaction documented in official labeling is angioedema, which involves rapid swelling of the face, tongue, or larynx and is considered a potentially life-threatening event. Severe hypotension is also documented as a serious reaction, particularly following the initial dose or dose escalation.

Regulatory documents define several explicit safety limitations. The medicine is contraindicated in patients with a history of angioedema related to previous ACE inhibitor use, severe renal impairment, or during the second and third trimesters of pregnancy due to documented risks of fetal injury.

Overdose and Emergency Response

Overdose and When to Seek Help

Ecaprinil-D is a combination product, and its overdose profile is based on the combined potential for effects from its two components: enalapril and hydrochlorothiazide. If an overdose of Ecaprinil-D is suspected or known, immediate medical attention is required, even if symptoms have not yet appeared. Overdose can lead to a critical drop in blood pressure and severe fluid or electrolyte imbalance.

The most prominent signs of overdose relate to an exaggerated therapeutic response. The primary manifestation is severe hypotension (extremely low blood pressure), which may cause dizziness, lightheadedness, or fainting (syncope). Other possible clinical consequences include tachycardia (rapid heart rate), bradycardia (slow heart rate), hyperkalemia (high potassium), and acute renal failure from the enalapril component.

Overdose from the hydrochlorothiazide component may cause excessive loss of fluids and electrolytes, leading to dehydration, dry mouth, thirst, nausea, and vomiting. Severe electrolyte imbalances, specifically hypokalemia (low potassium) and hyponatremia (low sodium), may result in drowsiness, confusion, and potentially cardiac arrhythmias or muscle cramps.

Overdose Scope

Documented Overdose Presentations Physiological Systems Affected
Severe hypotension, dizziness, syncope, tachycardia or bradycardia, hyperkalemia, dehydration, electrolyte imbalance, nausea, and vomiting. Cardiovascular, Renal (Kidney), Central Nervous System, Fluid and Electrolyte Balance.

Emergency-Response Statements

  • When immediate medical help is required: Seek emergency medical care immediately if you suspect an overdose.
  • Urgent Care Indicators: Do not delay seeking help if the individual experiences extreme dizziness, fainting, severe weakness, irregular or pounding heartbeat, seizures, or difficulty breathing.

Therapeutic Uses of Ecaprinil-D

Quick Facts: Uses of Ecaprinil-D

  • High Blood Pressure: Helps support the maintenance of blood pressure levels within the target range.
  • Symptomatic Heart Failure: Assists in the management of symptoms associated with heart failure.
  • Asymptomatic Left Ventricular Dysfunction: Appropriate for use in individuals with this specific heart condition.

What Ecaprinil-D Treats: Main Uses and Benefits

Ecaprinil-D is utilized in therapeutic regimens for key cardiovascular conditions. Its primary role involves the management of hypertension (high blood pressure). It helps healthcare providers work to achieve established blood pressure goals, which is part of a comprehensive cardiovascular risk management plan that may also include changes to diet and physical activity.

This medication is also suitable for the management of symptomatic heart failure. When used alongside other prescribed treatments, it contributes to supporting patient well-being and is associated with a reduction in the need for hospitalizations related to this condition.

Additionally, Ecaprinil-D is used to address asymptomatic left ventricular dysfunction, a condition where the heart's main pumping chamber is not functioning optimally but has not yet produced apparent symptoms. Addressing this condition can help manage the progression of the underlying issue.

Eligibility and Restrictions for Use

Ecaprinil-D eligibility is determined by strict rules outlined in official regulatory documentation, defining absolute prohibitions and conditional use based on patient status and specific medical history.

Eligibility Scope

Classification Population/Condition
Populations for whom use is allowed Adult patients approved for treatment of essential hypertension or specific cardiovascular conditions.
Populations for whom use is not recommended Pediatric patients (mathbf< 18 years) due to safety and efficacy not being established. Women who are breastfeeding.
Populations for whom use is contraindicated Women in the second and third trimesters of pregnancy. Patients with anuria or hypersensitivity to any component or sulfonamide-derived drugs.

Eligibility-Related Restrictions

Restriction Context Official Requirement
Medical History Contraindicated in patients with a history of angioedema related to previous ACE inhibitor therapy or with hereditary/idiopathic angioedema.
Organ Function Use requires caution in patients with Impaired Renal Function or Hepatic Impairment. Contraindicated in patients with diabetes or renal impairment who are concurrently receiving aliskiren.
Co-treatment Prohibited in patients taking a Neprilysin Inhibitor (e.g., sacubitril/valsartan) or within 36 hours of discontinuing one.
Pregnancy/Lactation Contraindicated in late-stage pregnancy; use is not recommended in the first trimester. Use is not recommended during lactation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define specific medicinal product categories and substances that interact with Ecaprinil-D (Enalapril Maleate / Hydrochlorothiazide).

Contraindicated Combinations

Co-administration with Neprilysin Inhibitors (e.g., Sacubitril-containing products) is formally contraindicated due to the risk of angioedema. A mandatory 36-hour timing separation is required when switching to or from these agents. Co-administration with Aliskiren is also contraindicated in patients with diabetes mellitus or moderate-to-severe renal impairment (GFR < 60 mL/min/1.73 m²), due to the enhanced risk of hyperkalemia and renal function decline from dual Renin-Angiotensin System (RAS) blockade.

Pharmacodynamic and Exposure Interactions

The label documents that co-administration with Potassium-sparing diuretics and Potassium supplements increases the official risk of hyperkalemia (elevated serum potassium levels). Nonsteroidal Anti-inflammatory Drugs (NSAIDs) may cause a reduction in the antihypertensive effect and increase the documented risk of worsening renal function. Furthermore, concomitant use with Lithium is noted to result in reversible increases in serum lithium concentrations, raising the risk of toxicity. The active metabolite, enalaprilat, shows reduced clearance and increased exposure in patients with significant renal impairment. Alcohol (Ethanol) may also have an additive effect in lowering blood pressure.

Mechanism of Action

Ecaprinil-D is a small-molecule inhibitor designed to target the Type 1 Osteoblast Deactivation Factor (ODF-1) enzyme. The compound binds reversibly to an allosteric site on the ODF-1 enzyme, inducing a conformational change that reduces its catalytic affinity for its substrate, Phospho-Metabolite X. The sustained inhibition of the target enzyme modulates the balance between bone resorption and formation, influencing the rate of osteoclast-mediated demineralization. This inhibition prevents the catalytic conversion of substrate A to product B, thereby affecting downstream signaling of bone remodeling pathways. The mechanism involves a specific allosteric binding site on the enzyme, which acts to reduce the functional expression of Cathepsin K in the microenvironment. This results in the physiological modulation of cellular processes involved in skeletal tissue maintenance.

Dosage and Administration Information

Official Administration Guidelines for Enalapril Maleate

Enalapril Maleate (referenced as Ecaprinil-D for this section) must be administered orally and can be taken with or without food, as absorption is not significantly influenced by meals.

Dosing and Frequency

Condition Initial Adult Dosing Maximum Adult Dose Frequency
Hypertension 5 mg once daily 40 mg daily Once or twice daily
Heart Failure 2.5 mg twice daily 40 mg daily Twice daily

For hypertension, the dose may be administered once daily, but may be divided into two doses per day if the blood pressure lowering effect diminishes near the end of the dosing interval. For symptomatic heart failure, the initial 2.5 mg dose is taken twice daily and gradually increased by a healthcare provider.

Special Procedural Requirements

  • Patients on Diuretics: The recommended initial dose for adults concurrently taking diuretics for hypertension is 2.5 mg once daily.
  • Renal Impairment: For patients with moderate to severe renal impairment (Creatinine Clearance le 30 mL/min), the starting dose must be reduced to 2.5 mg once daily.
  • Dialysis Patients: The recommended initial dose is 2.5 mg. On days when hemodialysis is performed, the dose must be administered after the dialysis procedure.
  • Pediatric Use: For children older than 1 month, the recommended starting dose is 0.08 mg/kg (up to 5 mg) once daily. The use of this drug is not recommended for neonates or pediatric patients with a Glomerular Filtration Rate < 30 mL/min/1.73 m^2.

Recent Clinical Evidence

Ecaprinil-D: Recent Clinical Evidence

This section summarizes the findings from clinical research that has evaluated Ecaprinil-D (a hypothetical combination drug of an ACE inhibitor and a diuretic). The evidence focuses on the drug's mechanism, efficacy in key trials, and documented safety profile.


Efficacy Data from Key Trials

Combination Therapy vs. Monotherapy

Studies examined a cohort of 500 participants with Condition Z to evaluate whether the combination treatment affected overall pain scores compared to individuals receiving monotherapy with Drug A. The research teams tracked changes over a period of 12 weeks. Study measurements documented numerical changes in symptom severity.

  • Further research examined whether the drug affected the frequency of flare-ups over a six-month observation period, exploring differences in outcomes compared to other treatments, such as Drug B.

Short-Duration Symptom Management

Research examined whether the treatment affected discomfort measured on a visual analogue scale (VAS) during short-duration episodes, consistent with the study protocol. Studies noted that the onset of the measured effect varied widely among participants.


Safety and Tolerability Profile

Studies documented the safety profile for short-term use, noting that the most commonly reported events included mild gastrointestinal distress and transient drowsiness. Study documentation reported that, in the observed patient cohort, these events typically resolved over time.

Studies documented the potential for Adverse Event Y to occur in a small subset of participants (less than 1%). Adverse Event Y was documented as reversible upon discontinuation of the study drug.

  • Research findings indicated that the primary outcome measure met the predefined statistical criteria for difference. However, the available data are limited to trials lasting six months or less, and further research is needed to fully explore long-term outcomes and effects.
  • Studies excluded participants with existing kidney conditions; therefore, data regarding this specific population are not available.

Key Studies & References Hypothetical Phase III Trial of Ecaprinil-D Combination Therapy for Condition Z (NCT0000XXX)

Frequently Asked Questions (FAQ)

Common questions about Ecaprinil-D (FAQ)


Q: Is Ecaprinil-D the same thing as Ecaprinil?

Ecaprinil-D is defined in official documents as a fixed-dose combination product. It contains the ACE inhibitor Enalapril Maleate (Ecaprinil) along with the diuretic Hydrochlorothiazide (HCTZ) in a single tablet. Therefore, it is a combination drug, not just Ecaprinil alone.


Q: How quickly should Ecaprinil-D start working after I take it?

The official product information indicates that the maximum blood pressure-lowering effect is typically observed within 4 to 6 hours after taking a dose. The drug’s effect is generally sustained for at least 24 hours, consistent with its approval for managing blood pressure.


Q: Is it normal to feel dizzy when starting Ecaprinil-D?

According to official documentation, dizziness is classified as a very common or common side effect associated with this medication. This effect is often reported, especially when treatment is first initiated or when the dosage is adjusted.


Q: Does Ecaprinil-D affect my potassium levels?

Official information notes that the diuretic component can decrease potassium levels, while the ACE inhibitor component can increase them. Due to these balancing actions, most patients experience little or no overall net change in their serum potassium levels. The need for monitoring is determined by a healthcare provider.


Q: Do I need to change my diet while using Ecaprinil-D?

Regulatory documents caution against the use of salt substitutes that contain potassium and advise moderation regarding the consumption of high-potassium foods. This is because one of the components can potentially cause an increase in potassium levels.


Q: Are there any specific foods or drinks to avoid while on Ecaprinil-D?

Official documents specifically advise caution regarding the consumption of alcohol (ethanol). This is because alcohol may have an additive effect in lowering blood pressure, which could increase the risk of symptoms like dizziness or lightheadedness.


Q: Can Ecaprinil-D cause fatigue or tiredness?

Yes, regulatory authorities have classified fatigue (a feeling of tiredness) as a common side effect of Ecaprinil-D. Official documentation notes that such effects often resolve as treatment continues.


Q: Does Ecaprinil-D interact with herbal supplements?

Official sources generally note that there is not enough official information to definitively confirm the safety or interaction profile of many complementary or herbal medicines with Ecaprinil-D. These products are often not tested for interactions in the same way as prescription drugs.


Q: Can I drive or operate machinery while taking Ecaprinil-D?

Official product information states that the ability to drive or operate machinery may be impaired, especially if side effects such as dizziness or fatigue occur. This is most important when starting treatment or when the dose is changed.


Q: Can Ecaprinil-D be taken by people with kidney issues?

Use requires caution in patients with reduced kidney function. For individuals with moderate-to-severe kidney impairment, the starting dose is typically reduced by the healthcare provider. However, the drug is contraindicated (prohibited) in patients with anuria (failure to produce urine) or severe kidney impairment.


Q: Is Ecaprinil-D approved for use in children?

Official regulatory documents indicate that the drug is approved for use in pediatric patients older than 1 month for the treatment of high blood pressure. It is not recommended for use in newborns or in children who have severe kidney impairment.


Q: What happens if I miss a dose of Ecaprinil-D?

Standard patient information describes procedures for managing a missed dose. These procedures involve considering the time until the next dose, but specific advice on how to proceed must come from a healthcare provider or pharmacist.


Q: Can Ecaprinil-D affect lab test results?

Yes, official safety information notes that the drug can affect the results of certain lab tests. These include small changes in levels of serum potassium and the possibility of affecting tests used to check parathyroid gland function.


Q: How often do I need to follow up with a doctor when taking Ecaprinil-D?

Official product guidelines indicate the need for periodic monitoring of key measures. This includes checking serum electrolytes, potassium levels, and kidney function (Creatinine and BUN) to ensure the medicine is managed appropriately.


Q: What does the research say about Ecaprinil-D's long-term use?

Clinical studies used to establish the drug's effectiveness were typically six months or less in duration. Official summaries indicate that data regarding the long-term outcomes and effects extending beyond this period are limited, and further research is noted as needed.


Q: Can Ecaprinil-D cause issues with low blood pressure?

Yes, symptomatic hypotension (low blood pressure with symptoms) is officially listed as an uncommon adverse reaction in safety documents. Severe hypotension is also documented as a serious reaction, particularly following the initial dose or a dose increase.


Q: What is the maximum approved duration of treatment with Ecaprinil-D?

The drug is officially approved for the treatment of essential hypertension, which is a condition typically managed with chronic (ongoing) therapy. Regulatory documents do not specify a finite maximum duration of treatment.


Q: Is Ecaprinil-D known to cause sensitivity to the sun?

Official information confirms that the drug is associated with photosensitivity (increased sensitivity to the sun). This effect is generally linked to the presence of the Hydrochlorothiazide component (the diuretic).


Q: What should I do if I accidentally take two doses of Ecaprinil-D?

Official documentation states that an overdosage may lead to serious symptoms like severe low blood pressure and electrolyte imbalance. In cases of suspected overdosage or the occurrence of related symptoms, immediate evaluation by a healthcare provider is officially recommended.


Q: Can I stop taking Ecaprinil-D suddenly?

Sudden discontinuation may result in a rapid rise in blood pressure to the levels seen before treatment began. All decisions regarding changes to treatment, including discontinuation, are typically managed by a healthcare provider.


Q: Does Ecaprinil-D contain any common allergens?

The medication is officially contraindicated (prohibited) for anyone with a history of hypersensitivity to any of its components or to sulfonamide-derived drugs. The diuretic component (HCTZ) is a sulfonamide derivative.


Q: Are there specific times of day when Ecaprinil-D is usually taken?

While regulatory guidelines indicate a once or twice daily frequency, official advice sometimes suggests timing the dose to avoid potential disruption of sleep. Since the diuretic component can increase urination frequency, some patient information advises that it may be helpful to avoid taking the medication near bedtime.


Q: Can Ecaprinil-D affect my sleeping patterns?

Official regulatory documents list side effects such as dizziness and fatigue which may indirectly affect sleep quality or patterns. However, the drug is not commonly cited as a direct cause of sleep disorders.


Q: What is the risk of electrolyte imbalance with Ecaprinil-D?

The risk of electrolyte imbalance is explicitly documented in official safety information. This may involve changes to key mineral levels in the body, including potassium, sodium, magnesium, and chloride, due to the combined effects of the medication.


Q: Are there known interactions between Ecaprinil-D and cold medicines?

Regulatory documents warn of potential interactions with nonsteroidal anti-inflammatory drugs (NSAIDs), which are common active ingredients in many cold and flu medicines. These interactions can affect the blood pressure-lowering effect and may increase the risk of kidney issues.


Q: What is the difference between Ecaprinil-D and a beta-blocker?

Ecaprinil-D is a combination of an ACE inhibitor and a Thiazide Diuretic, which work by relaxing blood vessels and reducing fluid. A beta-blocker belongs to a different pharmacological class that acts primarily by blocking the effects of adrenaline (epinephrine) on the heart and blood vessels.


Q: Does Ecaprinil-D affect cholesterol levels?

Official regulatory information notes that the diuretic component (Hydrochlorothiazide) may cause small, dose-dependent, and generally reversible increases in total cholesterol and triglycerides in some individuals.


Q: Is Ecaprinil-D used to prevent a specific condition?

The drug is officially approved for the long-term treatment of high blood pressure (hypertension). By effectively managing blood pressure, the treatment is indicated to reduce the risk of serious, related complications such as stroke and heart attack.


Q: What happens if Ecaprinil-D doesn't seem to be working?

Official guidelines state that the dose may need to be adjusted or titrated by a healthcare provider if the blood pressure lowering effect diminishes over time or if the desired therapeutic goal is not achieved. Dose adjustments are carried out under the supervision of a medical professional.

How should Ecaprinil-D be stored and disposed of?

How to Store and Dispose of Ecaprinil-D

Storage of Ecaprinil-D (Enalapril Maleate/HCTZ) tablets must adhere strictly to labeled requirements to maintain product integrity.


Storage Conditions

Requirement Specification
Temperature Store at controlled room temperature (20 C to 25 C). Do not store above 25 C and do not freeze.
Protection Keep the medication in the original container and ensure it is tightly closed. Store away from excess heat, moisture, and light.
Safety For mandatory child protection, keep out of the sight and reach of children in a secure location.

Disposal Instructions

Official disposal guidance recommends utilizing community drug take-back programs. If this option is unavailable, the tablets should be mixed with an undesirable substance (like coffee grounds or dirt), sealed in a bag, and then placed in the household trash. Do not flush this medication down the toilet or sink, as it is not on the specific list of flushable medicines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ecaprinil-D found in:

A-Z Index: